1. Home
  2. NTLA vs SHLS Comparison

NTLA vs SHLS Comparison

Compare NTLA & SHLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • SHLS
  • Stock Information
  • Founded
  • NTLA 2014
  • SHLS 1996
  • Country
  • NTLA United States
  • SHLS United States
  • Employees
  • NTLA N/A
  • SHLS N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SHLS Semiconductors
  • Sector
  • NTLA Health Care
  • SHLS Technology
  • Exchange
  • NTLA Nasdaq
  • SHLS Nasdaq
  • Market Cap
  • NTLA 1.2B
  • SHLS 1.1B
  • IPO Year
  • NTLA 2016
  • SHLS 2021
  • Fundamental
  • Price
  • NTLA $9.21
  • SHLS $8.98
  • Analyst Decision
  • NTLA Buy
  • SHLS Buy
  • Analyst Count
  • NTLA 20
  • SHLS 21
  • Target Price
  • NTLA $23.53
  • SHLS $9.18
  • AVG Volume (30 Days)
  • NTLA 11.1M
  • SHLS 8.1M
  • Earning Date
  • NTLA 11-06-2025
  • SHLS 11-04-2025
  • Dividend Yield
  • NTLA N/A
  • SHLS N/A
  • EPS Growth
  • NTLA N/A
  • SHLS N/A
  • EPS
  • NTLA N/A
  • SHLS 0.19
  • Revenue
  • NTLA $57,528,000.00
  • SHLS $433,993,000.00
  • Revenue This Year
  • NTLA $8.51
  • SHLS $18.27
  • Revenue Next Year
  • NTLA N/A
  • SHLS $13.96
  • P/E Ratio
  • NTLA N/A
  • SHLS $47.76
  • Revenue Growth
  • NTLA 33.52
  • SHLS 2.68
  • 52 Week Low
  • NTLA $5.90
  • SHLS $2.71
  • 52 Week High
  • NTLA $28.25
  • SHLS $11.36
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 30.06
  • SHLS 44.53
  • Support Level
  • NTLA $12.15
  • SHLS $8.66
  • Resistance Level
  • NTLA $13.69
  • SHLS $10.03
  • Average True Range (ATR)
  • NTLA 1.51
  • SHLS 0.69
  • MACD
  • NTLA -1.34
  • SHLS -0.27
  • Stochastic Oscillator
  • NTLA 0.69
  • SHLS 14.21

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About SHLS Shoals Technologies Group Inc.

Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.

Share on Social Networks: